GLP‑1 Drugs: From Weight Loss to Addiction Treatment
Jun 25, 2026
/assets/images/provider/photos/2850790.png)
GLP‑1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) have transformed obesity management. But new research suggests they may also reduce cravings and compulsive behaviors, opening doors to addiction treatment.
Exploring how GLP‑1 therapies may transform both obesity and addiction care.
At Transcend Rejuvenation, we stay ahead of these medical innovations, offering personalized consultations online and nationwide delivery of treatments to ensure accessibility for all clients.
What Are GLP‑1 Drugs?
- GLP‑1 (Glucagon‑Like Peptide‑1) is a hormone that regulates appetite and blood sugar.
- Medications mimic GLP‑1, slowing digestion, reducing hunger, and improving insulin sensitivity.
- Originally developed for type 2 diabetes, they are now FDA‑approved for weight loss.
The Link Between GLP‑1 and Addiction
Recent studies (watch this ABC News Special for reference) show GLP‑1 drugs may:
- Reduce dopamine surges linked to addictive substances.
- Lower cravings for alcohol, nicotine, and even opioids.
- Improve impulse control, helping patients resist compulsive behaviors.
This makes GLP‑1 a game‑changing candidate for addiction therapy, complementing traditional counseling and rehabilitation.
Benefits Beyond Weight Loss
- Dual impact: Supports weight management and addiction recovery.
- Improved mental health: Reduced anxiety and depression linked to cravings.
- Better long‑term outcomes: Patients may sustain healthier lifestyles.
Why Choose Transcend Rejuvenation?
- Expert guidance: Our medical professionals provide free online consultations tailored to your needs.
- Nationwide delivery: Treatments are shipped safely across the USA, ensuring accessibility.
- Holistic approach: We combine science, lifestyle coaching, and emotional support.